Silverback Current Deferred Revenue vs Total Liab Analysis

SPRY Stock

12.57 0.39 3.20%

Silverback Therapeutics financial indicator trend analysis is much more than just breaking down Silverback Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Silverback Therapeutics is a good investment. Please check the relationship between Silverback Therapeutics Current Deferred Revenue and its Total Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silverback Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Silverback Stock please use our How to Invest in Silverback Therapeutics guide.

Current Deferred Revenue vs Total Liab

Current Deferred Revenue vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Silverback Therapeutics Current Deferred Revenue account and Total Liab. At this time, the significance of the direction appears to have very week relationship.

The correlation between Silverback Therapeutics' Current Deferred Revenue and Total Liab is 0.23. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Total Liab in the same time period over historical financial statements of Silverback Therapeutics, assuming nothing else is changed. The correlation between historical values of Silverback Therapeutics' Current Deferred Revenue and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Silverback Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Current Deferred Revenue i.e., Silverback Therapeutics' Current Deferred Revenue and Total Liab go up and down completely randomly.

Correlation Coefficient

0.23

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Silverback Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Silverback Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silverback Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Silverback Stock please use our How to Invest in Silverback Therapeutics guide.At this time, Silverback Therapeutics' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 1,489 in 2025, whereas Enterprise Value Over EBITDA is likely to drop (6.32) in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	36.8M	67.6M	77.7M	81.6M
Cost Of Revenue	17.3M	73K	84.0K	79.8K

Total Operating Expenses Cost Of Revenue

Silverback Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Other Liab	Net Tangible Assets	Current Deferred Revenue	Non Currrent Assets Other	Other Assets	Long Term Debt	Net Receivables
Total Assets		-0.93	-0.01	-0.85	0.93	-0.73	-0.87	-0.72	-0.79	0.87	-0.54	1.0	0.71	-0.12	0.95	0.93	-0.39	1.0	-0.84	-0.88	0.92	-0.92	0.07	0.92	-0.89	0.87
Short Long Term Debt Total	-0.93		0.23	0.98	-0.93	0.87	0.82	0.68	0.94	-0.82	0.74	-0.94	-0.81	-0.04	-0.93	-0.98	0.28	-0.94	0.96	0.96	-0.94	0.97	0.05	-0.95	0.93	-0.74
Other Current Liab	-0.01	0.23		0.42	0.05	0.55	-0.19	-0.05	0.53	0.21	0.78	-0.02	-0.29	-0.54	-0.25	-0.12	-0.41	-0.03	0.42	0.16	-0.01	0.16	0.39	-0.03	0.21	0.24
Total Current Liabilities	-0.85	0.98	0.42		-0.84	0.94	0.74	0.58	0.99	-0.74	0.87	-0.86	-0.8	-0.19	-0.9	-0.93	0.13	-0.86	0.99	0.92	-0.87	0.93	0.16	-0.88	0.92	-0.61
Total Stockholder Equity	0.93	-0.93	0.05	-0.84		-0.65	-0.79	-0.82	-0.78	0.8	-0.47	0.93	0.85	-0.29	0.9	0.98	-0.57	0.93	-0.81	-0.92	1.0	-0.92	0.23	1.0	-0.84	0.88
Property Plant And Equipment Net	-0.73	0.87	0.55	0.94	-0.65		0.71	0.29	0.96	-0.7	0.95	-0.74	-0.57	-0.42	-0.8	-0.76	-0.12	-0.74	0.97	0.77	-0.67	0.79	0.31	-0.69	0.82	-0.44
Net Debt	-0.87	0.82	-0.19	0.74	-0.79	0.71		0.39	0.66	-1.0	0.44	-0.87	-0.39	-0.07	-0.74	-0.77	0.17	-0.87	0.78	0.74	-0.75	0.8	0.07	-0.76	0.78	-0.72
Retained Earnings	-0.72	0.68	-0.05	0.58	-0.82	0.29	0.39		0.52	-0.4	0.2	-0.72	-0.87	0.49	-0.69	-0.79	0.68	-0.72	0.48	0.75	-0.84	0.75	-0.29	-0.84	0.65	-0.72
Accounts Payable	-0.79	0.94	0.53	0.99	-0.78	0.96	0.66	0.52		-0.66	0.92	-0.8	-0.78	-0.23	-0.88	-0.88	0.09	-0.8	0.98	0.87	-0.81	0.88	0.16	-0.82	0.86	-0.55
Cash	0.87	-0.82	0.21	-0.74	0.8	-0.7	-1.0	-0.4	-0.66		-0.43	0.87	0.41	0.05	0.74	0.78	-0.19	0.87	-0.77	-0.76	0.76	-0.81	-0.06	0.77	-0.79	0.72
Non Current Assets Total	-0.54	0.74	0.78	0.87	-0.47	0.95	0.44	0.2	0.92	-0.43		-0.55	-0.56	-0.53	-0.67	-0.63	-0.26	-0.55	0.88	0.66	-0.51	0.66	0.41	-0.53	0.71	-0.21
Cash And Short Term Investments	1.0	-0.94	-0.02	-0.86	0.93	-0.74	-0.87	-0.72	-0.8	0.87	-0.55		0.72	-0.1	0.95	0.93	-0.38	1.0	-0.85	-0.89	0.92	-0.93	0.06	0.92	-0.89	0.87
Common Stock Shares Outstanding	0.71	-0.81	-0.29	-0.8	0.85	-0.57	-0.39	-0.87	-0.78	0.41	-0.56	0.72		-0.25	0.78	0.89	-0.51	0.72	-0.71	-0.87	0.89	-0.82	0.17	0.89	-0.74	0.64
Non Current Liabilities Total	-0.12	-0.04	-0.54	-0.19	-0.29	-0.42	-0.07	0.49	-0.23	0.05	-0.53	-0.1	-0.25		-0.13	-0.12	0.95	-0.1	-0.25	-0.04	-0.27	-0.07	-0.94	-0.24	-0.24	-0.55
Other Current Assets	0.95	-0.93	-0.25	-0.9	0.9	-0.8	-0.74	-0.69	-0.88	0.74	-0.67	0.95	0.78	-0.13		0.91	-0.42	0.95	-0.89	-0.85	0.91	-0.87	0.15	0.91	-0.82	0.85
Other Stockholder Equity	0.93	-0.98	-0.12	-0.93	0.98	-0.76	-0.77	-0.79	-0.88	0.78	-0.63	0.93	0.89	-0.12	0.91		-0.42	0.93	-0.89	-0.97	0.99	-0.97	0.06	0.99	-0.91	0.79
Total Liab	-0.39	0.28	-0.41	0.13	-0.57	-0.12	0.17	0.68	0.09	-0.19	-0.26	-0.38	-0.51	0.95	-0.42	-0.42		-0.38	0.07	0.26	-0.56	0.23	-0.89	-0.53	0.05	-0.76
Total Current Assets	1.0	-0.94	-0.03	-0.86	0.93	-0.74	-0.87	-0.72	-0.8	0.87	-0.55	1.0	0.72	-0.1	0.95	0.93	-0.38		-0.85	-0.89	0.92	-0.93	0.06	0.92	-0.89	0.87
Short Term Debt	-0.84	0.96	0.42	0.99	-0.81	0.97	0.78	0.48	0.98	-0.77	0.88	-0.85	-0.71	-0.25	-0.89	-0.89	0.07	-0.85		0.88	-0.82	0.9	0.19	-0.83	0.89	-0.59
Other Liab	-0.88	0.96	0.16	0.92	-0.92	0.77	0.74	0.75	0.87	-0.76	0.66	-0.89	-0.87	-0.04	-0.85	-0.97	0.26	-0.89	0.88		-0.94	0.98	0.13	-0.95	0.96	-0.66
Net Tangible Assets	0.92	-0.94	-0.01	-0.87	1.0	-0.67	-0.75	-0.84	-0.81	0.76	-0.51	0.92	0.89	-0.27	0.91	0.99	-0.56	0.92	-0.82	-0.94		-0.93	0.21	1.0	-0.85	0.86
Current Deferred Revenue	-0.92	0.97	0.16	0.93	-0.92	0.79	0.8	0.75	0.88	-0.81	0.66	-0.93	-0.82	-0.07	-0.87	-0.97	0.23	-0.93	0.9	0.98	-0.93		0.16	-0.94	0.98	-0.68
Non Currrent Assets Other	0.07	0.05	0.39	0.16	0.23	0.31	0.07	-0.29	0.16	-0.06	0.41	0.06	0.17	-0.94	0.15	0.06	-0.89	0.06	0.19	0.13	0.21	0.16		0.17	0.33	0.54
Other Assets	0.92	-0.95	-0.03	-0.88	1.0	-0.69	-0.76	-0.84	-0.82	0.77	-0.53	0.92	0.89	-0.24	0.91	0.99	-0.53	0.92	-0.83	-0.95	1.0	-0.94	0.17		-0.86	0.84
Long Term Debt	-0.89	0.93	0.21	0.92	-0.84	0.82	0.78	0.65	0.86	-0.79	0.71	-0.89	-0.74	-0.24	-0.82	-0.91	0.05	-0.89	0.89	0.96	-0.85	0.98	0.33	-0.86		-0.57
Net Receivables	0.87	-0.74	0.24	-0.61	0.88	-0.44	-0.72	-0.72	-0.55	0.72	-0.21	0.87	0.64	-0.55	0.85	0.79	-0.76	0.87	-0.59	-0.66	0.86	-0.68	0.54	0.84	-0.57

Click cells to compare fundamentals

Silverback Therapeutics Account Relationship Matchups

Silverback Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	26.4M	61.4M	281.4M	233.2M	268.2M	136.0M
Short Long Term Debt Total	10.0M	9.0M	481K	274K	246.6K	234.3K
Other Current Liab	915K	1.3M	2.9M	1.4M	1.6M	1.9M
Total Current Liabilities	8.2M	8.2M	5.4M	2.4M	2.2M	2.0M
Total Stockholder Equity	(14.1M)	(31.3M)	272.9M	230.8M	265.4M	278.6M
Property Plant And Equipment Net	23K	693K	774K	824K	741.6K	1.1M
Net Debt	(14.5M)	(51.0M)	(210.0M)	(70.7M)	(63.6M)	(66.8M)
Retained Earnings	(22.0M)	(42.3M)	(76.9M)	(131.3M)	(118.2M)	(112.3M)
Accounts Payable	1.2M	1.8M	1.7M	759K	683.1K	648.9K
Cash	24.5M	60.1M	210.5M	71.0M	81.6M	82.7M
Non Current Assets Total	25K	716K	3.7M	1.5M	1.3M	1.8M
Cash And Short Term Investments	24.5M	60.1M	274.4M	228.4M	262.6M	131.4M
Common Stock Shares Outstanding	34.7M	28.9M	40.0M	95.2M	109.5M	115.0M
Liabilities And Stockholders Equity	26.4M	61.4M	281.4M	233.2M	268.2M	136.0M
Non Current Liabilities Total	32.2M	84.5M	3.1M	37K	33.3K	31.6K
Other Current Assets	1.5M	666K	2.3M	2.6M	3.0M	1.7M
Other Stockholder Equity	50.2M	87.0M	349.4M	362.0M	416.3M	437.1M
Total Liab	40.5M	92.7M	8.5M	2.4M	2.2M	2.1M
Total Current Assets	26.4M	60.7M	277.7M	231.7M	266.5M	133.6M
Short Term Debt	2.6M	3.6M	460K	237K	213.3K	202.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
V	Visa Class A
C	Citigroup

Additional Tools for Silverback Stock Analysis

When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Silverback Current Deferred Revenue vs Total Liab Analysis

Current Deferred Revenue vs Total Liab

Current Deferred Revenue vs Total Liab Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Total Liab

Silverback Therapeutics fundamental ratios Correlations

Silverback Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Silverback Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Silverback Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Other Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Assets	+ 1.0	Net Tangible Assets

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.98	Short Long Term Debt Total
Current Deferred Revenue	- 0.97	Other Stockholder Equity
Other Liab	- 0.97	Other Stockholder Equity
Other Assets	- 0.95	Other Liab
Other Assets	- 0.95	Short Long Term Debt Total